Merck stock rises on sales of its blockbuster cancer drug Keytruda
Merck’s stock jumped 3% to about $130 during Thursday morning trading after the New Jersey-based pharmaceutical company reported higher than expected sales of its blockbuster cancer drug Keytruda.